Literature DB >> 10683441

The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.

F Acquati1, M Accarino, C Nucci, P Fumagalli, L Jovine, S Ottolenghi, R Taramelli.   

Abstract

We applied cDNA selection methods to a genomic clone (YAC 761B5) from chromosome 21 located in the so-called 'Down critical region' in 21q22.3. Starting from human fetal heart and brain mRNAs we obtained and sequenced several cDNA clones. One of these clones (Down region aspartic protease (DRAP), named also BACE2 according to the gene nomenclature) revealed a striking nucleotide and amino acid sequence identity with several motifs present in members of the aspartic protease family. In particular the amino acid sequences comprising the two catalytic sites found in all mammalian aspartic proteases are perfectly conserved. Interestingly, the predicted protein shows a typical membrane spanning region; this is at variance with most other known aspartic proteases, which are soluble molecules. We present preliminary evidence, on the basis of in vitro translation studies and cell transfection, that this gene encodes a glycosylated protein which localizes mainly intracellularly but to some extent also to the plasma membrane. Furthermore DRAP/BACE2 shares a high homology with a newly described beta-secretase enzyme (BACE-1) which is a transmembrane aspartic protease. The implications of this finding for Down syndrome are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683441     DOI: 10.1016/s0014-5793(00)01192-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

1.  BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.

Authors:  Weihui Zhou; Fang Cai; Yu Li; George S Yang; Kathleen D O'Connor; Robert A Holt; Weihong Song
Journal:  J Mol Neurosci       Date:  2010-05-09       Impact factor: 3.444

2.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.

Authors:  Debomoy K Lahiri; Bryan Maloney; Yuan-Wen Ge
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

4.  Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.

Authors:  Bryan Maloney; Yuan-Wen Ge; Nigel H Greig; Debomoy K Lahiri
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 5.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 6.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

7.  Upregulation of SET expression by BACE1 and its implications in Down syndrome.

Authors:  Xiaozhu Zhang; Yili Wu; Xiaoling Duan; Wei Chen; Haiyan Zou; Mingming Zhang; Shuting Zhang; Fang Cai; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

8.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

9.  Expression of reticulon 3 in Alzheimer's disease brain.

Authors:  H Kume; Y Konishi; K S Murayama; F Kametani; W Araki
Journal:  Neuropathol Appl Neurobiol       Date:  2009-04       Impact factor: 8.090

Review 10.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.